Clinical trial CLDK378A2303
A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2012-005637-36 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01828112 |
| Inclusion criteria | Anaplasic lymphoma kinase (ALK) positive |
| Last update |